| November 2, 2010 |
2:00-3:00PM |
Registration for Workshops |
| 3:00-4:00PM |
Workshop 1
CEO Roundtable: The New New World in HCV – Beyond the First-Generation Protease Inhibitors
The HCV market is at an inflection point. With the much anticipated approval of telaprevir and boceprevir, patients’ treatment outcome is expected to dramatically improve. But these agents are not likely to be the final answer. A strong group of pipeline products, many with innovative mechanism of action are steadfastly moving through clinical trials and continue to impress with data. We will convene a panel of CEOs leading this wave of innovations to map out the future of HCV.
Paul Zhang
Principal
Easton Associates, LLC
Plus additional panelists. Please check back for additional details. |
| 4:00-4:30PM |
Break |
| 4:30-5:30PM |
Workshop 2 - Campbell Alliance |
| 5:30-7:00PM |
Registration and Welcome Reception
All TA attendees and speakers are invited to attend our welcome reception. |
| November 3, 2010 |
7:30AM |
Registration & Continental Breakfast |
| 8:15AM |
Welcome and Introductory Remarks |
| 8:15-8:45AM |
Keynote plenary talk
Therapeutic Area Challenges and Opportunities: Who Will Win, Who Won’t, and Where Are You in the Mix
- What forces are reshaping the dealmaking landscape?
- Which therapeutic areas attract the most number of deals and alliance dollars?
- What are the top acquisitions within the therapeutic areas?
- How will changes in financing, reimbursement and regulation affect the therapeutic areas?
|
8:45-10:00AM |
Keynote plenary talk followed by roundtable of business development leaders
Scientific Innovation and Industry Barriers: Rethinking the Business Development Model for Hard Times
Stephen Friend, MD, PhD
CEO and Cofounder
Sage Bionetworks
Former Senior Vice President and Franchise Head for Oncology Research
Merck & Co.
- Human disease biology is so complex, interconnected, and expensive to research that the existing dominant business strategies have done little to improve productivity. What new ways of thinking can break down barriers to new medicines and how can partnering drive the process?
Keynote Panel with Pharma’s Business Development Leaders
Leveraging Insights to Pick Targets and Deal Models that are Likely to Succeed
- How are your recent deals showing your strategic priorities, esp. in specific TAs?
- How is your size or other advantages making you the most attractive partner for a particular asset? How do you position your company as the best partner of choice amongst increasingly competitive assets?
- How do you see healthcare reform impacting your dealmaking strategy?
- Which technologies/therapeutic areas are driving the most interest based on your strategic priorities and why?
- Deal structures that allow large and small companies to share risk : Do you like to do options-based deals? Smaller up fronts?
- Early stage vs. late stage: What are the priorities?
- What needs to change in R&D and in partnering?
David H. Donabedian, PhD, MBA
Vice President, Strategic Alliances, US CEEDD
GlaxoSmithkline
Polly Murphy
VP, R&D Business Development
Pfizer Inc.
Sridaran Natesan, Ph.D.
Distinguished Scientist
Head of External Innovations and Partnering
Sanofi-Aventis |
| 10:00-10:15 |
Networking and Refreshment Break |
| 10:15AM |
Track 1 NEUROSCIENCE
Track 2 INFLAMMATORY/AUTOIMMUNE
Track 3 ONCOLOGY
Track 4 CARDIOVASCULAR/METABOLIC
Track 5 INFECTIOUS DISEASES
Track 6 HOT SPACE
Top 10 Projects to Watch: Most Licensable Products
- The Top 10, with each area analyst explaining the selection process and criteria and briefly describing the programs and companies chosen.
|
| 10:15-11:00AM |
Track 1
NEUROSCIENCE
Matchmaking in Neuro Drug Partnering: Identifying the Right Drugs and the Right Partners
- Challenges in identifying good neuro science
- Market statistics and market potential
- Competitive landscape
- Where the most promising neuro drug programs are coming from
Harry M. Tracy, PhD, President, NI Research
Roundtable Discussion
Creating New Opportunities and Partnerships in Neuroscience Drug Programs
- The most problematic and exciting mechanisms now under development
- Catching CNS drug issues early on: minimizing later costs and risks
- CNS trial design issues: which add to cost and risk?
- Designing partnerships to share risks and responsibilities more effectively—who should do what?
John Hixon
Senior Director, Global New Product Planning - Neuroscience
Eli Lilly and Company
Darryle D. Schoepp, Ph.D.
Senior Vice President and Franchise Head, Neuroscience
Merck and Company, Inc.
|
Track 2
INFLAMMATORY/AUTOIMMUNE
Matchmaking in Inflammatory/Autoimmune Drug Partnering: Identifying the Right Drugs and the Right Partners
- Challenges in identifying good science
- Market statistics and market potential
- Competitive landscape
- Where the most promising drug programs are coming from
Roundtable Discussion
Creating New Opportunities and Partnerships in Inflammatory/ Autoimmune Drug Programs
- The most problematic and exciting mechanisms now under development
- What recent outcomes and the latest deals reveal about the space
- Practical advice on how to find the right partner
- How to gauge the impact of regulatory and reimbursement changes
Peter Blume Jensen*
Executive Director, External Scientific Affairs
Daiichi Sankyo
Patrick Griffin*
Head, External Innovation and Opportunities
Immuno-Inflammation Therapeutic Strategy Unit
Sanofi-Aventis
Augustine Yee*
Senior Director of Global Corporate Development
AstraZeneca
|
Track 3
ONCOLOGY
Matchmaking in Oncology Drug Partnering: Identifying the Right Drugs and the Right Partners
- Challenges in identifying good oncology science
- Market statistics and market potential
- Competitive landscape
- Where the most promising oncology drug programs are coming from
Presented by Ben Bonifant, Campbell Alliance
Roundtable Discussion
Creating New Opportunities and Partnerships in Oncology Drug Programs
- The most problematic and exciting mechanisms now under development
- Reviewing oncology drug development issues early: the substantial impact on the development of the drug that might save you on cost and risk later
- What recent outcomes and the latest deals reveal about the space
- Practical advice on how to find the right partner
- The impact of the coming flood of new oncology products
Anna Protopapas
Senior Vice President,
Corporate Development and Strategy
Millennium: The Takeda Oncology Company
Paul Bolno*
VP, Oncology R & D
Business Development
GlaxoSmithkline
Joyce Pei*
Director, Global Business Development, Pharma Partnering
Roche
Erle Mast
Executive Vice President and CFO
Clovis Oncology, Inc.
|
|
Track 1-Top 10 Neuroscience Projects to Watch |
Track 2-Top 10 Inflammatory Projects to Watch |
Track 3-Top 10 Oncology Projects to Watch |
One-on-One Partnering Meetings |
| 11:00-12:00PM |
Company Presentations |
Company Presentations |
Company Presentations |
| 12:00-1:15PM |
Luncheon for All Speakers and Delegates |
|
Track 1-Top 10 Neuroscience Projects to Watch |
Track 2-Top 10 Inflammatory Projects to Watch |
Track 3-Top 10 Oncology Projects to Watch |
One-on-One Partnering Meetings |
| 1:15-2:15PM |
Company Presentations |
Company Presentations |
Company Presentations |
| 2:15-3:00PM |
Track 4
CARDIOVASCULAR/ METABOLIC
Matchmaking in CV/Metabolic Drug Partnering: Identifying the Right Drugs and the Right Partners
- Challenges in identifying good science
- Market statistics and market potential
- Competitive landscape
- Where the most promising drug programs are coming from
Track 4 CARDIOVASCULAR/ METABOLIC
Roundtable Discussion
Creating New Opportunities and Partnerships in Cardiovascular/Metabolic Drug Programs
- The most exciting and problematic mechanisms now under development
- How to respond to cardioprevention
outcomes issues?Are we ready to narrow our labels?
- Can we change the CV drug development process to establish earlier proof of concept and safety?
- How will novel biomarkers be validated and become clinically useful?
- Will CV dealmaking revive?
John Delyani, PhD
Head, Strategic Alliances
Novartis Institutes for BioMedical Research
Finn Benned Hansen*
Vice President and Head of Business Development
Novo Nordisk
Pierre Chancel*
SVP Global Marketing & Access
SVP, Global Diabetes
Sanofi-Aventis
|
Track 5
INFECTIOUS DISEASES
Matchmaking in Infectious Diseases: Identifying the Right Drugs and the Right Partners
- Challenges in identifying good science
- Market statistics and market potential
- Competitive landscape
- Where the most promising drug programs are coming from
Track 5
INFECTIOUS DISEASES
Roundtable Discussion
Creating New Opportunities and Partnerships in Infectious Disease Drug Programs
- The most problematic and exciting mechanisms now under development
- What deals in the space reveal about growth potential
- Will the rise of resistant strains lead to explosive growth?
- Where are the future commercial opportunities strongest?
Mary Graves*
Head of Infectious Diseases Partnering
Roche
Melissa Faris*
Director, Scientific Licensing, Infectious Diseases and Opthalmology
GlaxoSmithkline
|
Track 6
HOT SPACE
Matchmaking in Drug Partnering: Identifying the Right Drugs and the Right Partners
- Challenges in identifying good science
- Market statistics and market potential
- Competitive landscape
- Where the most promising drug programs are coming from
Track 6
HOT SPACE
Roundtable Discussion
Creating New Opportunities and Partnerships in High Value Therapeutic Areas
- What are the opportunities in Rare diseases, women’s health, dermatology, bone and muscle disease, ophthalmology and other high value areas
- Is Big Pharma really ready to advance smaller market products?
- What recent deals reveal
- Starting small to grow big
Peter Wirth
Executive Vice President, Legal and Corporate Development
Genzyme Corporation
Deanna Petersen
SVP, Business Development
Shire
Alan Harris*
SVP, Global Project and Portfolio Management
Ferring Pharmaceuticals
|
|
Track 1-Top 10 Cardiovascular/Metabolic Projects to Watch |
Track 2-Top 10 Infectious Diseases Projects to Watch |
Track 3-Top 10 Hot Space Projects to Watch |
One-on-One Partnering Meetings |
| 3:00-5:30PM |
Company Presentations |
Company Presentations |
Company Presentations |
| 5:30-7:00PM |
Networking Reception |
| November 4, 2010 |
8:00AM |
Registration / Welcome Coffee |
9:00-9:30AM |
Keynote Session
Rainmaking in a Drought: Financing Innovation, Innovating Finance
The current valuation of companies has driven many traditional venture investors from the market. What alternatives are emerging and how can companies tap into innovative financing sources?How can biotechnology ventures build valuation and attract investment while maintaining their long-term strategic objectives? |
9:30-10:30AM |
Investor Panel: Creative Risk Sharing and Alternative Funding Strategies for Today’s Biotech
Investors from traditional venture capital and private equity, pharmaceutical strategic venture funds, and nonprofit foundations describe interesting recent deals and discuss how the rising risks and costs of drug development and the desperation of biotechs for funds have led to more creative risk sharing and a turn to nondilutive funding sources.
Ulrik Spork
Managing Partner
Novo Growth Equity
Bill Maris*
Managing Director
Google Ventures
Brenda Gavin
Managing Partner
Quaker BioVentures
Margaret Anderson
Executive Director
FasterCures/The Center for Accelerating Medical Solutions |
10:30-2:00PM |
One-on-one Partnering Meetings |
1:00PM |
Lunch |
2:00PM |
Conference Concludes |